---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057783"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:09:31.685102+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics appoints Arlene Morris to Board of Directors, effective May 6, 2024

## Summary
- Morris replaces Peter Thompson on the Audit and Compensation Committees.
- She brings 30+ years of biotech leadership, including CEO roles at Syndax and Affymax.
- Annual cash retainer of $40,000 plus $7,500 for Audit and $5,000 for Compensation Committee service.
- New director stock option grant with ~$500,000 fair value, vesting monthly over 3 years.
- Appointment fills vacancy left by Kenneth Harrison's resignation in June 2023.

## SEC filing metadata
- accession: 0001104659-24-057783
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465924057783/0001104659-24-057783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465924057783/tm2413446d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057783
- JSON: https://secwatch.observer/filing/0001104659-24-057783.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057783.txt

## Key facts
- Executive change
  Arlene Morris was appointed as Director at Edgewise Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465924057783/0001104659-24-057783-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.